Get the latest news, insights, and market updates on VANI (Vivani Medical, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani Medical Inc. (NASDAQ:VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenatide GLP-1 implant NPM-115, representing the first-in-human test of the company's proprietary NanoPortal implant technology. Exenatide is sold by AstraZeneca Plc (NASDAQ:AZN) under the brand names Byetta and Bydureon BCise to treat type 2 diabetes. LIBERATE-1 Study Results The study met its primary objectives, which were to evaluate the NPM-115 implant's safety and tolerability profile and Aug 5, 2025 - $VANI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple